Adage Capital Partners
AMLX icon

Adage Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Adage Capital Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Sell
1,900,000
-1,660,764
-47% -$25.7M 0.05% 360
2026
Q1 		$49.5M Buy
3,560,764
+783,709
+28% +$11M 0.08% 251
2025
Q4 		$33.5M Sell
2,777,055
-4,039,773
-59% -$54.9M 0.05% 342
2025
Q3 		$92.6M Sell
6,816,828
-1,983,172
-23% -$18.7M 0.15% 140
2025
Q2 		$56.4M Buy
8,800,000
+3,102,395
+54% +$15.1M 0.1% 206
2025
Q1 		$20.2M Buy
+5,697,605
New +$20.3M 0.04% 411
2023
Q4 		– Sell
-1,700,200
Closed -$31.1M – 853
2023
Q3 		$31.1M Buy
1,700,200
+932,000
+121% +$19.7M 0.07% 289
2023
Q2 		$16.6M Sell
768,200
-239,136
-24% -$6.46M 0.04% 463
2023
Q1 		$29.6M Sell
1,007,336
-901,865
-47% -$31.3M 0.07% 322
2022
Q4 		$70.5M Buy
1,909,201
+559,201
+41% +$19.8M 0.17% 151
2022
Q3 		$38M Buy
1,350,000
+1,150,000
+575% +$28.7M 0.09% 230
2022
Q2 		$3.85M Buy
200,000
+162,800
+438% +$1.93M 0.01% 830
2022
Q1 		$478K Buy
+37,200
New +$840K ﹤0.01% 956

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Adage Capital Partners's AMLX Position: Q2 2026 in Review

Adage Capital Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 47% in Q2 2026, selling an estimated $25.7M and leaving 1,900,000 shares worth $34.1M. The position accounts for 0.05% of the portfolio, ranked #360.

Adage Capital Partners first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $92.6M in Q3 2025. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Adage Capital Partners held 1,900,000 shares of Amylyx Pharmaceuticals worth $34.1M as of Q2 2026.
  • Adage Capital Partners sold 1,660,764 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $25.7M.
  • Amylyx Pharmaceuticals made up 0.05% of Adage Capital Partners's portfolio in Q2 2026, its #360 holding.
  • Adage Capital Partners first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Adage Capital Partners's Amylyx Pharmaceuticals position peaked at $92.6M in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.